Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
CLSD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.29 - $1.65
Previous CloseN/A
Volume106.43K
Average Volume (3M)8.92M
Market Cap
$31.56M
Enterprise Value$109.13M
Total Cash (Recent Filing)$9.38M
Total Debt (Recent Filing)$533.00K
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 18, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding78,510,315
10 Day Avg. Volume491,383
30 Day Avg. Volume8,919,701
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.46
Enterprise Value/Revenue26.20
Enterprise Value/Gross Profit29.62
Enterprise Value/Ebitda-6.02
Forecast
1Y Price Target
$2.50Price Target Upside509.76% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Strategic AlternativesCLSD announced plans to explore a full range of strategic alternatives with an investment bank to advance its CLS-AX program and maximize shareholder value.
Trial ResultsThe Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results, maintaining stable BCVA and CST from baseline to Week 36.
Bears Say
Funding ChallengesCLSD is facing difficulties in securing funding or partnerships to advance its CLS-AX program into phase 3 development.
Operational ChangesCLSD has paused all internal R&D programs and remaining employees, including key executives, are transitioning into consultant roles to conserve cash.
Clearside Biomedical News
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.29 and its highest was $1.65 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $31.56M.
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is Aug 18, 2025 which is 4 days ago.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on May 14, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.002.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -0.1.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 78,510,315 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSD
Clearside Biomedical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.50 (509.76% Upside)
$2.50 (509.76% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.58%
12-Months-Change
Fundamentals
Return on Equity
91.63%
Trailing 12-Months
Asset Growth
-54.82%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
CLSD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.View all CLSD earnings summariesCLSD Stock 12 Month Forecast
Average Price Target
$2.50
▲(509.76% Upside)
Technical Analysis
Ownership Overview
1.44% Insiders
4.73% Mutual Funds
3.24% Other Institutional Investors
87.00% Public Companies and
Individual Investors